InflaRx (IFRX) Research & Development (2016 - 2026)

InflaRx has disclosed Research & Development across 11 years of filings, most recently posting -$5.5 million for Q2 2026.

• In Q2 2026, Research & Development rose 32.44% year-over-year to -$5.5 million; the TTM figure through Jun 2026 stood at -$23.8 million (up 63.68% YoY), while the FY2025 annual figure was -$29.1 million, up 23.1% from the prior year.
• Research & Development came in at -$5.5 million for Q2 2026 at InflaRx, down from -$4.9 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $11.9 million in Q2 2022 to a low of -$44.1 million in Q4 2023.
• Average Research & Development over 5 years is -$13.0 million, with a median of -$8.1 million recorded in 2023.
• Year-over-year, Research & Development tumbled 199.66% in 2023 and soared 83.8% in 2025.
• Over 5 years, Research & Development stood at -$38.3 million in 2022, then declined by 15.29% to -$44.1 million in 2023, then increased by 14.39% to -$37.8 million in 2024, then soared by 83.8% to -$6.1 million in 2025, then rose by 10.04% to -$5.5 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were -$5.5 million in Q2 2026, -$4.9 million in Q1 2026, and -$6.1 million in Q4 2025.